Reflection Biotechnologies (ReflectionBio®) is a patient-driven biotechnology company that focuses on developing gene therapy and other breakthrough treatments for rare diseases. Rare disease patients shoulder the inevitable odds of genetic mutations for mankind but are often neglected by the society. Rare disease research and orphan drug development are grossly under-supported by public funding and research resources. ReflectionBio® is one of the first biotech companies in the world that is driven directly by rare disease patients. Our founder, Richard Yang, is a rare disease patient and a member of the “Orphan Drug Development Guidebook” Task Force of the International Rare Diseases Research Consortium (IRDiRC). As a patient-driven company, we created and apply a “By Patients, For Patients” TM approach for patients to combine efforts in driving R&D to help ourselves and others.
ReflectionBio® focuses on developing gene therapy and other innovative treatments for rare diseases. Our gene therapy pipeline product, RBIO-101, has received Orphan Drug Designation from the U.S. FDA for treating Bietti Crystalline Dystrophy (BCD). BCD is a blinding retinal disease. Currently, there is no approved treatment available for BCD. Our R&D efforts and progress bring hope to tens of thousands of BCD patients worldwide.